Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication. Alecensa ...

Draft guidance consultation NICE guideline 12 May 2025 Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909) [ID6434] Draft guidance Technology appraisal guidance ...

EU approves expanded use of ABBV's Rinvoq and AZN's Imfinzi and Enhertu. NVS set to invest $23B to boost U.S. manufacturing.

A phase 3 trial – called TeliMET-NSCLC-01 ... in c-Met-positive, non-squamous NSCLC, in patients both with and without other gene mutations including EGFR and ALK. Other drugmakers have ...

The collaborators will present positive preclinical data from a study of its ... antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized ...

Despite solid data, the lack of high-value indications and no unique platform makes Nuvalent's valuation seem inflated; I ...

Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients ...

Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients ...

Data suggest that taletrectinib “provides clinically meaningful tumor shrinkage and prolonged disease control as a treatment option for advanced ROS1+ NSCLC, regardless of treatment history,” ...

Enriqueta Felip, MD, PhD, discusses the design of the phase 3 3475A-D77 trial evaluating subcutaneous pembrolizumab in metastatic NSCLC.

From new KRAS and HER2 inhibitors to home-administered immunotherapy, recent trials mark a turning point in how metastatic lung cancer is managed.

Lung cancer is the number one cancer killer in the world. Biomarker testing improves outcomes in stage IV non-small cell lung cancer (NSCLC), however its ...